From Bio프롬바이오
377220 · KOSDAQ · ₩377220 · 프롬바이오
₩1,909▼ ₩20 (1.04%)End-of-day · Oct 28, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩72B | ₩67B | ₩67B | ₩99B | ₩135B |
| Cost of sales | ₩31B | ₩30B | ₩21B | ₩30B | ₩33B |
| Gross profit | ₩42B | ₩37B | ₩46B | ₩69B | ₩102B |
| Operating income | −₩19B | −₩24B | −₩15B | ₩897M | ₩11B |
| Net income | −₩23B | −₩26B | −₩12B | ₩1.3B | ₩11B |
| Net income to shareholders | −₩22B | −₩25B | −₩11B | ₩3.2B | ₩11B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩65B | ₩81B | ₩97B | ₩94B | ₩96B |
| Current assets | ₩18B | ₩29B | ₩38B | ₩54B | ₩72B |
| Cash and equivalents | ₩2.3B | ₩2B | ₩6.4B | ₩1.8B | ₩8.1B |
| Total liabilities | ₩39B | ₩32B | ₩22B | ₩6.8B | ₩12B |
| Current liabilities | ₩37B | ₩27B | ₩22B | ₩6.4B | ₩12B |
| Borrowings | ₩6B | ₩4.5B | ₩18B | — | — |
| Total equity | ₩26B | ₩49B | ₩75B | ₩87B | ₩84B |
| Shareholders' equity | ₩28B | ₩50B | ₩77B | ₩88B | ₩84B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | −₩10B | −₩15B | −₩21B | −₩2B | −₩1.2B |
| Capital spending | ₩1.1B | ₩893M | ₩17B | ₩14B | ₩8.8B |
| Free cash flow | −₩11B | −₩16B | −₩38B | −₩16B | −₩10B |
Consolidated where available. Amounts in won.
Also known as: From Bio / 프롬바이오 / 377220 / KRX:377220
Source: KRX statistical information